Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1841 results
October 2015
-
Media Release
Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
Solid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core… -
Media Release
Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis
Cosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of… -
Media Release
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma
With four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the… -
Story Discovery
Clinical trials make a move toward mice
By growing human tumors in mice, NIBR develops a unique system that seeks to mimic clinical trials of cancer drugs
-
Story Access to Healthcare
Delivering access: first launch in Kenya
Chronic diseases kill 38 million people per year worldwide; almost three-quarters of those deaths occur in low- and middle-income countries. It’s time to act.
-
Story Discovery
Getting down to the roots of Alzheimer’s disease
Experimental treatments for Alzheimer’s disease put the amyloid cascade hypothesis to the test.
-
Story Discovery
Stopping Alzheimer's disease before it starts
Novartis collaborates with the Banner Alzheimer’s Institute to test treatments for preventing Alzheimer’s disease.
-
Media Release
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
Novartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and… -
Featured News
Industry and academia collaborating to innovate for patients
We are partnering with the Friedrich Miescher Institute on more than 50 research projects to improve and extend people’s lives.
-
Media Release
Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years
Late-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had… -
Media Release
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years
NEDA-4 - no evidence of disease activity based on four parameters - relapses, MRI lesions, brain shrinkage and disability progression - is a comprehensive measure of MS disease control 31.2%… -
Story Patient Perspectives
Debunking the myths about multiple sclerosis
We surveyed 7,000 people in seven countries to find out what they know about multiple sclerosis (MS). Our survey identified several surprising misconceptions.